Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6425
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCody F. Priceen
dc.contributor.authorJohn P. Wooden
dc.contributor.authorIsmail, Ibrahimen
dc.contributor.authorSmith, Simonen
dc.contributor.authorHanson, Joshen
dc.date.accessioned2024-10-09T02:18:57Z-
dc.date.available2024-10-09T02:18:57Z-
dc.date.issued2024-
dc.identifier.citationPrice CF, Wood JP, Ismail I, Smith S, Hanson J. The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia. Pathogens. 2024 Oct 29;13(11):943. doi: 10.3390/pathogens13110943. PMID: 39599496; PMCID: PMC11597851.en
dc.identifier.urihttps://dora.health.qld.gov.au/qldresearchjspui/handle/1/6425-
dc.descriptionCairns & Hinterland Hospital and Health Service (CHHHS) affiliated authors: Cody F. Price, John P. Wood, Ibrahim Ismail, Simon Smith, Josh Hansonen
dc.description.abstractIntroduction: Patients receiving biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for rheumatological conditions are at an increased risk of serious, potentially life-threatening, infection. However, the incidence, aetiology, and clinical course of serious infection in patients receiving b/tsDMARDs in tropical settings are incompletely defined. Methods: We retrospectively reviewed all patients with rheumatoid arthritis receiving b/tsDMARDs between October 2012 and October 2021, at Cairns Hospital in tropical Australia. The incidence, aetiology, and clinical course of serious infections (those requiring admission to hospital or parenteral antibiotics) were determined. Results: 310 patients had 1468 patient years of b/tsDMARD therapy during the study period; 74/310 (24%) had 147 serious infections translating to an overall risk of 10.0 episodes of serious infection per 100 patient years. The respiratory tract (50/147, 34%) and skin (37/147, 25%) were the most frequently affected sites. A pathogen was identified in 59/147 (40%) episodes and was most commonly Staphylococcus aureus (24/147, 16%). Only 2/147 (1%) were confirmed “tropical infections”: 1 case of Burkholderia pseudomallei and 1 case of mixed B. pseudomallei and community-acquired Acinetobacter baumannii infection. Overall, 13/147 (9%) episodes of serious infection required Intensive Care Unit admission (0.9 per 100-patient years of b/tsDMARD therapy) and 4/147 (3%) died from their infection (0.3 per 100-patient years of b/tsDMARD therapy). The burden of comorbidity and co-administration of prednisone were the strongest predictors of death or a requirement for ICU admission. Conclusions: The risk of serious infection in patients taking b/tsDMARDs in tropical Australia is higher than in temperate settings, but this is not explained by an increased incidence of traditional tropical pathogens.en
dc.language.isoenen
dc.relation.ispartofPathogensen
dc.subjectinfectious diseasesen
dc.subjectimmunosuppressionen
dc.subjecttropical medicineen
dc.subjectrheumatoid arthritisen
dc.subjectAboriginal and Torres Strait Islander peoplesen
dc.subjecttropical Australiaen
dc.titleThe Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australiaen
dc.typeArticleen
dc.identifier.doi10.3390/pathogens13110943-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypeArticle-
Appears in Sites:Cairns & Hinterland HHS Publications
Forensic and Scientific Services Publications
Show simple item record

Page view(s)

14
checked on Jan 22, 2025

Download(s)

4
checked on Jan 22, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.